Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 53

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients: The effect of Δ9-THC on visceral sensitivity

Klooker, T. K., Leliefeld, K. E. M., Van Den Wijngaard, R. M., Boeckxstaens, G. E. E.·2011·Neurogastroenterology & Motility
DOI 10.1111/j.1365-2982.2010.01587.x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2982.2010.01587.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 30

  1. Camilleri, 2001, Management of the irritable bowel syndrome, Gastroenterology, 120, 652, 10.1053/gast.2001.21908 · DOI · Paper page
  2. Bouin, 2002, Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds, Gastroenterology, 122, 1771, 10.1053/gast.2002.33601 · DOI · Paper page
  3. Mayer, 1994, Basic and clinical aspects of visceral hyperalgesia, Gastroenterology, 107, 271, 10.1016/0016-5085(94)90086-8 · DOI
  4. Klooker, 2007, Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome, Aliment Pharmacol Ther, 4, 605, 10.1111/j.1365-2036.2007.03398.x · DOI
  5. Kuiken, 2005, Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 2, 157, 10.1111/j.1365-2036.2005.02524.x · DOI
  6. Posserud, 2007, Altered rectal perception in irritable bowel syndrome is associated with symptom severity, Gastroenterology, 133, 1113, 10.1053/j.gastro.2007.07.024 · DOI · Paper page
  7. Van D, 2008, Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome, Clin Gastroenterol Hepatol, 6, 321, 10.1016/j.cgh.2007.12.005 · DOI
  8. Mertz, 1995, Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, 40, 10.1016/0016-5085(95)90267-8 · DOI · Paper page
  9. Munakata, 1997, Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome, Gastroenterology, 112, 55, 10.1016/S0016-5085(97)70219-1 · DOI
  10. Massa, 2006, Endocannabinoids and the gastrointestinal tract, J Endocrinol Invest, 3, 47
  11. Walker, 2002, Cannabinoid analgesia, Pharmacol Ther, 95, 127, 10.1016/S0163-7258(02)00252-8 · DOI · Paper page
  12. Rice, 2002, Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy, Prostaglandins Leukot Essent Fatty Acids, 3, 243, 10.1054/plef.2001.0362 · DOI
  13. Sanson, 2006, Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats, Neurogastroenterol Motil, 18, 949, 10.1111/j.1365-2982.2006.00819.x · DOI
  14. Kikuchi, 2008, Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity, J Pharmacol Sci, 106, 219, 10.1254/jphs.FP0071599 · DOI
  15. Esfandyari, 2007, Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study, Am J Physiol Gastrointest Liver Physiol, 293, G137, 10.1152/ajpgi.00565.2006 · DOI
  16. Beaumont, 2009, Effect of Delta-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans, Br J Pharmacol, 156, 153, 10.1111/j.1476-5381.2008.00010.x · DOI
  17. Jaggar, 1998, The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain, Pain, 2, 189, 10.1016/S0304-3959(98)00041-4 · DOI
  18. Martin, 1999, Spinal cannabinoids are anti-allodynic in rats with persistent inflammation, Pain, 82, 199, 10.1016/S0304-3959(99)00045-7 · DOI
  19. Bridges, 2001, The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain, Br J Pharmacol, 133, 586, 10.1038/sj.bjp.0704110 · DOI
  20. Fox, 2001, The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain, Pain, 2, 91, 10.1016/S0304-3959(00)00474-7 · DOI · Paper page
  21. Johanek, 2001, Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms, Pain, 93, 303, 10.1016/S0304-3959(01)00336-0 · DOI
  22. Rukwied, 2003, Cannabinoid agonists attenuate capsaicin-induced responses in human skin, Pain, 102, 283, 10.1016/S0304-3959(02)00401-3 · DOI
  23. Richardson, 1998, Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors, Pain, 75, 111, 10.1016/S0304-3959(97)00213-3 · DOI
  24. Schwetz, 2004, Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 1, 123, 10.1111/j.1365-2036.2004.01774.x · DOI
  25. Izzo, 2008, Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects, Gut, 57, 1140, 10.1136/gut.2008.148791 · DOI
  26. Bortolato, 2005, The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats, Psychopharmacology (Berl), 177, 264, 10.1007/s00213-004-1941-4 · DOI
  27. Chaperon, 1999, Behavioral effects of cannabinoid agents in animals, Crit Rev Neurobiol, 13, 243, 10.1615/CritRevNeurobiol.v13.i3.20 · DOI · Paper page
  28. Dewey, 1986, Cannabinoid pharmacology, Pharmacol Rev, 38, 151, 10.1016/S0031-6997(25)06864-4 · DOI
  29. Monnikes, 2001, Role of stress in functional gastrointestinal disorders evidence for stress-induced alterations in gastrointestinal motility and sensitivity, Dig Dis, 19, 201, 10.1159/000050681 · DOI · Paper page
  30. Posserud, 2004, Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress, Gut, 53, 1102, 10.1136/gut.2003.017962 · DOI

Cited by

See all 53

Metadata

Authors
Klooker, T. K., Leliefeld, K. E. M., Van Den Wijngaard, R. M., & Boeckxstaens, G. E. E.
Venue
Neurogastroenterology & Motility
Publisher
Wiley
Published
2010-08-16
Volume
23
Issue
1
Pages
30-e2
ISSN
1350-1925
DOI
10.1111/j.1365-2982.2010.01587.x
Cited by
53
References
2
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1842 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients: The effect of Δ9-THC on visceral sensitivity. https://app.cochat.ai/papers/10.1111/j.1365-2982.2010.01587.x
The paper
Klooker, T. K., Leliefeld, K. E. M., Van Den Wijngaard, R. M., & Boeckxstaens, G. E. E. (2011). The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients: The effect of Δ9-THC on visceral sensitivity. Neurogastroenterology & Motility. https://doi.org/10.1111/j.1365-2982.2010.01587.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.